BS_9DFBHHB5
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 58.86990801576872
- age_years
- 0.929
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.560
- HEDGEHOG_SIGNALING+0.542
- INTERFERON_GAMMA_RESPONSE+0.538
- ALLOGRAFT_REJECTION+0.521
- TGF_BETA_SIGNALING+0.467
- IL6_JAK_STAT3_SIGNALING+0.454
- APICAL_SURFACE+0.390
- INFLAMMATORY_RESPONSE+0.383
- APOPTOSIS+0.360
- KRAS_SIGNALING_UP+0.354
Top 10 suppressed
- MYC_TARGETS_V2-0.425
- E2F_TARGETS-0.257
- OXIDATIVE_PHOSPHORYLATION-0.245
- DNA_REPAIR-0.203
- MYC_TARGETS_V1-0.189
- UNFOLDED_PROTEIN_RESPONSE-0.166
- G2M_CHECKPOINT-0.145
- SPERMATOGENESIS-0.137
- UV_RESPONSE_UP-0.130
- GLYCOLYSIS-0.092
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_014EVM2D | low-grade glioma | — | 0.921 |
| 2 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.915 |
| 3 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.909 |
| 4 | BS_VP5Y45Z7 | pilocytic astrocytoma | — | 0.909 |
| 5 | TCGA-F7-8489-01A-31R-2403-07 | — | — | 0.899 |
| 6 | MDT-AP-2029 | Med | Medulloblastoma | 0.898 |
| 7 | BS_JWSR581E | low-grade glioma | — | 0.896 |
| 8 | BS_MF9X3PKH | low-grade glioma | — | 0.896 |
| 9 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.889 |
| 10 | BS_V89HGTET | pilocytic astrocytoma | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.542 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.538 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.521 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.467 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.454 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.390 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.383 | Idelalisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.354 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.319 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.312 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.305 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.302 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.301 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.296 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.283 | Inavolisib | — uncovered |
| COAGULATION | 0.267 | Binimetinib | — uncovered |
| MYOGENESIS | 0.257 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.211 | Idelalisib | — uncovered |